This trial is studying a new molecule, DF1001, that targets the activation signals of natural killer (NK) cells and T-cells to receptors on cancer cells. The trial will occur in two phases, with the first phase testing different doses of DF1001 on patients with various types of solid tumors to see what is the best dose. The second phase will use the best dose from the first phase on patients with either selected solid tumors, or solid tumors expressing high levels of HER2.
4 Primary · 14 Secondary · Reporting Duration: From time of initiation of therapy until the date of first documented tumor progression, assessed up to 24 months
490 Total Participants · 22 Treatment Groups
Primary Treatment: DF1001 · No Placebo Group · Phase 1 & 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: